CollPlant Biotechnologies (FRA:CPT) Total Operating Expense: €10.63 Mil (TTM As of Mar. 2026)


FRA:CPT CollPlant Biotechnologies Ltd FRA:CPT
22 GF Score
Price €0.27
GF Value €0.23
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Total Operating Expense?

CollPlant Biotechnologies FRA:CPT 22 Total Operating Expense is €10.63 Mil as of Mar. 2026. GuruFocus rates FRA:CPT with a GF Score™ of 22/100 and a GF Value™ of €0.23 (Modestly Overvalued). The stock has 4 warning signs investors should review.

CollPlant Biotechnologies's Total Operating Expense for the three months ended in Mar. 2026 was €2.48 Mil. CollPlant Biotechnologies's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €10.63 Mil.

CollPlant Biotechnologies Total Operating Expense Related Terms

CollPlant Biotechnologies Total Operating Expense Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Total Operating Expense Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.01 16.05 15.11 15.42 11.12

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 2.75 2.82 2.58 2.48
FRA:CPT
22GF Score
CollPlant Biotechnologies Ltd FRA:CPT
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €10.63 Mil mean?
CollPlant Biotechnologies (FRA:CPT) has a Total Operating Expense of €10.63 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' Total Operating Expense too high?
CollPlant Biotechnologies' current Total Operating Expense is €10.63 Mil. Overall, CollPlant Biotechnologies has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Total Operating Expense compare to CPMV and TCRT?
CollPlant Biotechnologies' Total Operating Expense of €10.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current Total Operating Expense is €10.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.23, compared to a current price of €0.27 — trading 15.7% above its estimated fair value. The current Total Operating Expense is €10.63 Mil. CollPlant Biotechnologies' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current Total Operating Expense is €10.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of €0.27 is trading 15.7% above its estimated GF Value™ of €0.23. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for FRA:CPT:

  • Total Operating Expense: €10.63 Mil
  • GF Value™: €0.23 vs. price of €0.27 (15.7% above fair value)
  • GF Score™: 22/100 with 4 warning signs

No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Other Exchanges CLGN:USA
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
22GF Score

Get the complete analysis for FRA:CPT

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.23
GF Value